Drug Landscape ›
Additive solution ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 17
Most-reported reactions
Off Label Use — 6 reports (35.29%) Necrosis — 4 reports (23.53%) Soft Tissue Necrosis — 2 reports (11.76%) Blood Glucose Increased — 1 report (5.88%) Blood Pressure Increased — 1 report (5.88%) Loss Of Consciousness — 1 report (5.88%) Myocardial Infarction — 1 report (5.88%) Seizure — 1 report (5.88%)
Source database →
Additive solution in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Additive solution approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Additive solution in United States?
Etablissement Français du Sang is the originator. The local marketing authorisation holder may differ — check the official source linked above.